Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 19/20 | 0.62 |
| ▸ | BRD4 | O60885 | 4/20 | 0.62 |
| ▸ | BRD2 | P25440 | 1/20 | 0.53 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.53 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.53 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.53 |
| ▸ | EED | O75530 | 2/20 | 0.47 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.47 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.47 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.47 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31124661 | 0.85 | EZH2 (0.82) | EZH2BRD4BRD2BRD3BRDT | |
| SCHEMBL16197843 | 0.85 | EZH2 (0.73) | EZH2BRD4BRD2BRD3BRDT | |
| SCHEMBL18863744 | 0.79 | EZH2 (0.78) | EZH2BRD4BRD2BRD3BRDT | |
| SCHEMBL28795469 | 0.79 | EZH2 (0.64) | EZH2BRD4BRD2BRD3BRDT | |
| SCHEMBL17970320 | 0.78 | EZH2 (0.77) | EZH2BRD4BRD2BRD3BRDT | |
| SCHEMBL2588268 | 0.77 | EZH2 (0.75) | EZH2BRD4BRD2BRD3BRDT | |
| SCHEMBL31158046 | 0.77 | EZH2 (0.75) | EZH2BRD4BRD2BRD3BRDT | |
| SCHEMBL2592711 | 0.77 | EZH2 (0.75) | EZH2BRD4BRD2BRD3BRDT | |
| SCHEMBL12180165 | 0.77 | EZH2 (0.75) | EZH2BRD4BRD2BRD3BRDT | |
| SCHEMBL2593065 | 0.77 | EZH2 (0.75) | EZH2BRD4BRD2BRD3BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021035194-A1 | COMBINATION THERAPY OF A T CELL THERAPY AND AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITOR AND RELATED METHODS | JUNO THERAPEUTICS, INC. (US) | 2021-02-25 | — | — | WO | disclosed |